Please login to the form below

Not currently logged in

Mylan to develop Lantus, Humalog and NovoLog generics

Signs Indian biotech deal to compete with the big-selling insulin brands

Mylan has set its sights on bringing generic versions of three top-selling insulin brands to market.

The company has signed a collaboration deal with Biocon to develop and commercialise the Indian biotech firm's versions of Sanofi's Lantus, Lilly's Humalog and Novo Nordisk's NovoLog.

Together the three 'fast-acting' insulin brands are worth approximately $11.5bn and all three are expected to lose patent protection in the next couple of years.

Mylan hopes its deal with Biocon will allow it to be one of the first companies to launch generic versions of the insulins in developed pharma markets like the US.

Mylan's CEO Heather Bresch said: "This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential.

“Importantly, we believe we have the opportunity to be one of the first generic entrants in developed markets into the rapidly growing diabetes area, helping to address unmet needs and reduce the economic burden to those battling the disease and to the global healthcare system."

The collaboration, which adds to the US generics company's existing generic biologics partnership with Biocon, will see the firms share development, capital and certain other costs in order to bring the products to market.

Mylan will then have exclusive commercialisation rights in the US, Canada, Australia, New Zealand, the EU and European Free Trade Association countries through a profit-share arrangement with Biocon.

Mylan will also have co-exclusive commercialisation rights with Biocon in certain other markets around the world.

Biocon's chairman and managing director Kiran Mazumdar-Shaw said: "We are confident that together we can build a strong global presence in generic insulin analogs and provide access to affordable therapy options to physicians, healthcare providers and diabetes patients worldwide."

Established in 1978, Biocon is India's largest biotechnology company by revenue and its product portfolio includes the world's first Pichia-based recombinant human insulin, Insugen.

14th February 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...